This product has not been tested for freeze-thaw stability. However, in powder form, repeatedly removing this product from a freezer for the purpose of preparing fresh solutions, is not expected to be detrimental to the protein. Prepared solutions may be stored up to 1 week at 2 - 8 °C. It is not recommended to freeze stock solutions, as the freeze-thaw process may lead to protein degradation.
Please see the link below to review additional information available in the product datasheet:
https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/299/301/f4883pis.pdf
F4883
Fibrinogen from human plasma
35-65% protein (≥90% of protein is clottable).
Synonym(s):
Factor I
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|
About This Item
Form:
powder
Biological source:
human plasma
Mol wt:
α-chain 63.5 kDa, β-chain 56 kDa, γ chain 47 kDa (about 4% carbohydrate content), soluble dimer 340 kDa
Pricing and availability is not currently available.
biological source
human plasma
Quality Level
description
essentially plasmin(ogen) free
form
powder
quality
35-65% protein (≥90% of protein is clottable).
mol wt
α-chain 63.5 kDa, β-chain 56 kDa, γ chain 47 kDa (about 4% carbohydrate content), soluble dimer 340 kDa
concentration
35-65% protein (biuret)
technique(s)
cell culture | mammalian: suitable
solubility
0.9% NaCl: soluble
storage temp.
−20°C
General description
Fibrinogen was the first blood coagulation factor to be identified, and it is a precursor of fibrin protein. This protein is composed of two chains, each of which is composed of three chains- α, β and γ. These three subunits are coded by three genes located in the human chromosomal locus 4q23-q32, and spans 51kb.[1]
Application
Fibrinogen from human plasma has been used for-
- fibrinogen adsorption assay performed on swCNTs (single-walled carbon nanotubes)
- the characterization of fibrinogen structure in the presence of CNT using CD (Circular dichroism) spectroscopy and temperature scan[2]
- the preparation of RBC suspension obtained from venous blood of antecubital vein, to assess RBC aggregability[3]
- fibrinolysis assay performed on mouse embryonic fibroblasts (MEFs)[4]
- the preparation of fibrinogen-labeled gold (Fgn/Au)[5]
- the quantification of in vitro angiogenesis by human microvascular endothelial cells[6] and
- the assessment of fibrin-induced apoptosis and differentiation-regulation in trophoblast obtained from term human placentas.[7]
Biochem/physiol Actions
Acute phase protein that is part of the coagulation cascade of proteins.
Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.
Fibrinogen is an acute-phase inflammatory protein, which plays an essential role in blood clotting. Coronary heart disease is linked to the plasma levels of fibrinogen in Chinese population, and might have potential as a marker and risk factor for the same.[1] A -455 allele of fibrinogen β (FGB) chain is linked with poor survival in Caucasian women with Finnish stroke.[8] Ischemic stroke preceded by hyperfibrinogenemia has poor outcome, which is independent of the baseline fibrinogen concentration.[9]
Features and Benefits
Source material has tested negative for HIV and HBsAg.
Physical form
Lyophilized powder containing sodium citrate and sodium chloride.
Analysis Note
Protein determined by biuret
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
1 of 1
This Item | |||
|---|---|---|---|
| technique(s) cell culture | mammalian: suitable | technique(s) indirect ELISA: suitable | technique(s) cell culture | mammalian: suitable, immunoblotting: suitable | technique(s) - |
| biological source human plasma | biological source human plasma | biological source rat plasma | biological source human plasma |
| concentration 35-65% protein (biuret) | concentration - | concentration 60-80% (biuret) | concentration - |
| mol wt α-chain 63.5 kDa, γ chain 47 kDa (about 4% carbohydrate content), β-chain 56 kDa, soluble dimer 340 kDa | mol wt - | mol wt α-chain 63.5 kDa, β-chain 56 kDa, γ chain 47 kDa (about 4% carbohydrate content), soluble dimer 340 kDa | mol wt - |
| form powder | form powder | form powder | form lyophilized |
| UniProt accession no. | UniProt accession no. | UniProt accession no. | UniProt accession no. - |
Still not finding the right product?
Explore all of our products under Fibrinogen from human plasma
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
J G White
The American journal of pathology, 137(4), 989-998 (1990-10-01)
Glycoprotein (GP)IIb-IIIa receptors on human platelets in suspension and after surface activation bind a variety of specific antibodies and ligands and transport them across the outside of the plasma membrane by processes of clustering, patching and capping, and endocytosis to
Mika Martiskainen et al.
BMC neurology, 14, 137-137 (2014-06-25)
Women die of stroke more often than men. After menopause, the incidence of ischemic stroke increases rapidly. Elevated fibrinogen levels and smoking have been associated with an increased risk of stroke. In gene-cluster haplotype analyses, the beta-fibrinogen (FGB) promoter -455
A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation.
Ronen Ben-Ami et al.
American journal of physiology. Heart and circulatory physiology, 285(6), H2663-H2669 (2003-07-19)
Therapeutic administration of immunoglobulins (Ig) has the potential to precipitate thrombotic events. This phenomenon may be explained by red blood cell (RBC) aggregation, which can be potentiated by Ig. The contribution of plasma albumin and fibrinogen to Ig-induced RBC aggregation
Global Trade Item Number
| SKU | GTIN |
|---|---|
| F4883-5G | 04061833617953 |
| F4883-500MG | 04061833617946 |
| F4883-1G | 04061833617939 |
-
storage and thawing Is it possible to store at -20 freezer and repeated freezing and thawing
1 answer-
Helpful?
-
-
F4883-500MG contains Sodium Citrate and Sodium Chlorure. Is it possible to have their concentration ? What is the volume of sodium chloride we have to put in the bottle please?
1 answer-
This material is lyophilized from a solution of 75 mM NaCl (4.39 mg/mL), 10 mM Na Citrate (2.94 mg/mL). It can be solubilized in 0.85% (w/v) sodium chloride to 2 mg/ml, by layering the protein on top of the saline solution and placing it in a 37°C water bath for 4-6 hours, with gentle agitation.
Helpful?
-
-
Hello. For your F4883-500MG Fibrinogen product, is there 500mg of pure fibrinogen in the vial? Or is there 500 mg of reagent - of which a fraction is clottable Fibrinogen? Do you have preparation instructions for this reagent?
1 answer-
F4883-500MG contains 500 mg of solid. Fibrinogen can be solubilized in 0.85% (w/v) sodium chloride (2 mg/ml) by layering the protein on top of the saline solution and placing it in a 37 °C water bath for 4-6 hours with gentle agitation.
Helpful?
-